Skip to main content
main-content

06-06-2021 | ASCO 2021 | Conference coverage | Video

OlympiA: Adjuvant olaparib delays recurrence of BRCA-mutant breast cancer

Judy Garber reports on the phase 3 OlympiA study suggesting that adjuvant olaparib could be an option for the treatment of patients with early-stage breast cancer and germline BRCA variants (5:00).

Read transcript

ESMO Congress 2021

Access our ongoing coverage including the latest news and expert video interviews.

Image Credits